Clinical overview of the novel inotropic agent toborinone

Bibliography

• RUFFOLO RR: Dobutamine: review of pharmacology.Am. J. Med. Sci. (1987) 294:244–248.
   PubMed Web of Science ®Google Scholar
• LUDMER PL, WRIGHT RF, ARNOLD JM et al: Separation ofthe direct myocardial and vasodilator activities of milrinone administered by an intracoronary infusion technique. Circulation (1986) 73:130–137.
   PubMed Web of Science ®Google Scholar
• PACKER M, CARVER JR, RODEHEFFER RJ et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl. J. Med. (1991) 325:1468–1475.
   PubMed Web of Science ®Google Scholar
• •Established that PDE inhibitors had adverse effects on mortality in congestive heart failure.
   Google Scholar
• COHN JN, GREENBERG SO, LORELL BH et al.: A dose-dependent increase in mortality with vesnari-none among patients with severe heart failure. N Engl. J. Merl. (1998) 339:1810–1816.
   PubMed Web of Science ®Google Scholar
• •A report of the VEST trial which established that vesnari-none, an oral agent related to toborinone, had adverse effects on mortality in congestive heart failure.
   Google Scholar
• FUJIOKA T, TERAMOTO S, MORI T et al.: Novel positive inotropic agents: Synthesis and biological activities of 6- (3-amino-2-hydroxyprop oxy) -2 (1 H) -quinolinone derivatives. J. Med. Chem. (1992) 35 (20) :3607–3612.
   PubMed Web of Science ®Google Scholar
• OHNISHI A, TOYOKI T, OHNO T et al.: Pharmacoki-netics and pharmacodynamics of intravenous OPC-18790 in humans: a novel nonglycosidic inotropic agent. J. Clin. Pharmacol. (1994) 34 (2) :176–183.
   PubMed Web of Science ®Google Scholar
• KITANI M, MIYAMOTO G, NAGASAWA M et al.: Biotrans-formation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates. Drug Metab. Dispos. (1997) 25 (6):663–674.
   PubMed Web of Science ®Google Scholar
• HOSOKAWA T, MORI T, FUJIKI H et al.: Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action. Heart Vessels (1992) 7 (2):66–75.
   PubMedGoogle Scholar
• ENDOH M, KAWABATA Y, KATANO Y, NOROTA I: Effectsof a novel cardiotonic agent (+/-)-643-(3,4- dimethxy-benzylamino)-2-hydroxypropoxy]-2(1H)-quinol-inone (OPC-18790) on contractile force, cyclic AMP level and aequorin light transients in dog ventricular myocardium. J. Cardiovasc. Pharmacol. (1994) 23(5)723–730.
   Google Scholar
• •Determined that toborinone increases intracellular calcium levels.
   Google Scholar
• ITOH S, MORI T, YOSHIDA K et al.: Cardiovascular effects of the combination of OPC-18790 and dopamine in halothane-anesthetized dogs. Jpn. J. Pharmacol. (1995) 69 3:229–237.
   PubMedGoogle Scholar
• FUJIKI H, MORI T, TOMINAGA M: Effects of OPC-18790 on hemodynamics and the 6-adrenergic receptor pathway during long term infusion in conscious dogs. CHF (1996) 2:12–20.
   Google Scholar
• SEMENIUK LM, BELENKIE I, TYBERG JV: Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure. Circulation (1998) 98:58–63.
   PubMed Web of Science ®Google Scholar
• TAKASE H, ORITO K, MORI T: Positive inotropic andchronotropic effects of toborinone and its electro-physiological properties in the isolated hearts of rabbits and guinea-pigs. Arzneimittelforschung (1996) 46:579–586.
   PubMed Web of Science ®Google Scholar
• YANG T, SNYDERS DJ, RODEN DM: Inhibition of cardiacpotassium currents by the vesnarinone analog OPC-18790: comparison with quinidine and dofetilide. J. Pharmacol. Exp. Ther. (1997) 280:1170–1175.
   PubMed Web of Science ®Google Scholar
• •Sophisticated analysis of the electrophysiological properties of toborinone.
   Google Scholar
• ECHT DS, LEE JT, MURRAY KT: A randomized, double blind, placebo-controlled, dose ranging study of dofetilide in patients with inducible sustained ventricular arrhythmias. J. Cardiovasc. Electrophysiol (1995) 6:687–699.
   PubMed Web of Science ®Google Scholar
• YANG T, RODEN DM: Extracellular potassium modulation of drug block ofimplications for torsades depointes and reverse use-dependence. Circulation (1996) 93:407–411.
   PubMed Web of Science ®Google Scholar
• WU Z, AWAJI T, ABE H et al.: Effects of OPC-18790, a new positive inotropic agent, on canine ventricular arrhythmias. Jpn. J. Pharmacol. (1993) 63:399–404.
   PubMedGoogle Scholar
• GANZ P, BRAUNWALD E: Coronary blood flow and myocardial ischemia. In: Heart Disease. A textbook of cardiovascular medicine. Braunwald E (Ed.) W.B. Saunders Co., Philadelphia, USA (1997):1161–1183.
   Google Scholar
• ISHIKAWA M, MORI T, ITOH S et al.: Effects of OPC-18790, a new positive inotropic agent, on energetics in the ischaemic canine heart: a 31P-MRS study. Cardiovasc. Res. (1995) 30:299–306.
   PubMed Web of Science ®Google Scholar
• •Important study demonstrating energetic benefits of toborinone in ischaemic myocardium.
   Google Scholar
• ITOH S, MORI T, YOSHIDA K, FUJIKI H, TOMINAGA M, YABUUCHI: Cardiovascular effects of the combination of OPC-18790 and dopamine in halothane-anesthetized dogs. Jpn. J. Pharmacol (1995) 69:229–237.
   PubMedGoogle Scholar
• KASS DA, MIDEI M, GRAVES W, MAUGHAN WL: Use of a conductance (volume) catheter and transient inferior vena caval occlusion for rapid determination of pressure-volume relationships in man. Cathet. Cardio-vasc. Diagn. (1988) 15:192–202.
   PubMed Web of Science ®Google Scholar
• FELDMAN MD, PAK PH, WU CW et al.: Acute cardiovas-cular effects of OPC-18790 in patients with congestive heart failure. Time- and dose-dependence analysis based on pressure-volume relations. Circulation (1996) 93:474–483.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive analysis of the effects of toborinone inhuman subjects with congestive heart failure using pressure-volume analysis.
   Google Scholar
• MACGOWAN GA, HABER HL, COWART TD, TEDESCO C, WU C, FELDMAN MD: Direct myocardial effects of OPC-18790 in human heart failure: Beneficial effects on contractile and diastolic function demonstrated by intracoronary infusion with pressure-volume analysis. J. Am. Coll. Cardiol. (1998) 31:1344–1351.
   PubMed Web of Science ®Google Scholar
• ••Establishes the direct myocardial effects of toborione inhuman subjects with congestive heart failure using intraco-ronary infusion and pressure-volume analysis.
   Google Scholar
• KANDA H, YOKOTA M, ISHIHARA H, NAGATA K, KATO R, SOBUE T: A novel inotropic vasodilator, OPC-18790, reduces myocardial oxygen consumption and improves mechanical efficiency with congestive heart failure. Am. Heart J. (1996) 132:361–368.
   PubMed Web of Science ®Google Scholar
• ••Important study in human heart failure subjectsdemonstrating advantageous effects of toborinone on myocardial oxygen consumption.
   Google Scholar
• DAUTERMAN K, PAK PH, MAUGHAN WL et al.: Contribu-tion of external forces to left ventricular diastolic pressure: implication for the use of the Starling law. Ann. Intern. Med. (1995) 122:737–742.
   PubMed Web of Science ®Google Scholar
• HIRATA T, AKAMATSU T, HORINOKUCHI N, UCHIDA O, KURO M: Study on the effectiveness of toborinone (OPC-18790) in the treatment of heart failure in patients following cardiac surgery. Arzneimittelfor-schung (1999) 49:499–503.
   PubMed Web of Science ®Google Scholar
• TAKENAKA T, TAKEUCHI R, CLARK R: Reproductive and developmental toxicity studies of toborinone (1): Fertility study in rats by intravenous administration. Jpn Pharmacol. Ther. (1996) 24(8):77–83.
   Google Scholar
• TAKENAKA T, TAKEUCHI R, TAMAGAWA M: Reproduc-tive and developmental toxicity studies of toborinone (2): Teratogenicity study in rats by intravenous administration. Jpn Pharmacol. Ther. (1996) 24(8)85–96.
   Google Scholar
• MIYATAKE M, KOTOSAI K, TAMAGAWA M: Reproductive and developmental toxicity studies of toborinone (4): Perinatal and postnatal study in rats by intravenous administration. Jpn. Pharmacol. Ther. (1996) 24(0103–111.
   Google Scholar
• FURUHASHI T, KATO M, TAKAHASHI M, TAKENAKA T:Reproductive and developmental toxicity studies of toborinone (3): Teratogenicity study in rabbits by intravenous administration. Jpn. Pharmacol. Ther. (1996) 24(8):97–102.
   Google Scholar
• SHIMADA A, YAMAGUCHI K, SUZUKI S et al.: Generalpharmacology of toborinone. Jpn. Pharmacol. Ther. (1996) 24(9):95–113.
   Google Scholar
• MAKIN A, BEGG SE, GOPINATH C: The toxicity of toborinone (OPC-18790) to the dog by repeated intravenous administration. Jpn. Pharmacol. Ther. (1996) 24(9):37–48.
   Google Scholar
• ISHIHARA H, YOKOTA M, SOBUE T, SAITO H: Relation between ventriculoarterial coupling and myocardial energetics in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. (1994) 23:406–416.
   PubMed Web of Science ®Google Scholar
• MAGORIEN RD, UNVERFERTH DV, BROWN GP, LEIER CV: Dobutamine and hydralazine: comparative influences of positive inotropy and vasodilation on coronary blood flow and myocardial energetics in nonischemic congestive heart failure. J. Am. Coll. Cardiol (1983) 1:499–505.
   PubMed Web of Science ®Google Scholar
• GILL JS, CAMM AJ: Management of arrhythmias inpatients with heart failure: Evaluation and treatment with drugs and devices. In: Heart Failure. Poole Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS (Eds.) Churchill Livingstone, New York, USA (1997):747–758.
   Google Scholar